How should transfusion choices be adjusted for sickle cell disease patients with alloimmunization risk?

Master the CAMLPR Transfusion Test with interactive questions and detailed explanations. Boost your knowledge and ensure you're exam-ready with comprehensive study resources!

Alloimmunization risk in sickle cell patients comes from repeatedly exposing the immune system to non-self red blood cell antigens during transfusions. To minimize this risk, transfusion planning should go beyond ABO/RhD and actively limit exposure to additional antigens. Extended antigen matching reduces the chance of forming new antibodies by aligning more of the recipient’s and donor’s antigen profiles, while phenotype or even genotype matching provides a precise map to guide unit selection.

Thorough antibody testing helps identify existing alloantibodies so future units can be chosen as antigen-negative, and leukoreduction decreases immune activation from donor leukocytes, further lowering sensitization and some transfusion-related immune complications. Together, these steps create a robust strategy to prevent alloimmunization and preserve transfusion options for the patient over time. In practice, clinicians would routinely provide extended antigen–matched units, use phenotype/genotype information to guide matching, perform comprehensive antibody screening, and apply leukoreduction as appropriate.